HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama
Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm clinical study to preliminarily observe and evaluate the
efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil
and leucovorin synchronous combined with Bevacizumab and Toripalimab as the first-line
therapy for advanced HCC.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborator:
Second Affiliated Hospital of Guangzhou Medical University